

Conference Schedule / Thursday May 3, 2012

7:30-8:30 **Breakfast and Registration** (2nd Level, Grand Banking Hall)

8:30-8:45 **Welcome and Introduction**

Michael Sherar, President & CEO, Cancer Care Ontario

David Jaffray, Acting Chair, UT DRO

8:45-9:30 **Keynote Address**

Growth and Acceptance of SBRT for Treatment of Primary and Metastatic Cancers

Paul Okunieff

Objectives: After this session, the attendees will be able to

- discuss staging metastases in defining new clinical trials.
- define evidence of oligometastases.
- discuss historical successes of local treatments for control of metastases.

9:30-9:45 **Question and Answer Period**

9:45-10:15 **Break**

10:15-11:45 **Session 1 – Lung Cancer**

Moderator: Patrick Cheung

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to and discuss the technical aspects of delivering SBRT in lung cancers.
- discuss the need for quality assurance and apply standards of care when adopting new treatment techniques.

10:15-10:35 *Should SBRT be the Standard of Care for Medically Inoperative Early Stage Lung Cancer?*

David Palma

10:35-10:45 Question and Answer Period

10:45-11:05 *Technologic Advances in Lung SBRT*

Jean-Pierre Bissonnette

11:05-11:15 Question and Answer Period

11:15-11:35 *Should there be Provincial Guidelines Regarding the Use of SBRT?*

Patrick Cheung

11:35-11:45 Question and Answer Period

11:45-1:15 **Lunch**

Conference Schedule / Thursday May 3, 2012

1:15-2:45 **Session 2 – Prostate Cancer**

Moderator: Michael Sharpe

Objectives: After this session, the attendees will be able to

- compare and contrast clinical outcomes related to the use of SBRT and HDR Brachytherapy in prostate cancer.
- discuss the technical aspects of delivering HDR Brachytherapy for prostate cancer.

1:15-1:35 *HDR or LDR Brachytherapy for Prostate Cancer?*
Gerard Morton

1:35-1:45 Question and Answer Period

1:45-2:05 *SBRT: Is this the Future of Radiotherapy for Prostate Cancer?*
Andrew Loblaw

2:05-2:15 Question and Answer Period

2:15-2:35 *Physics Issues in HDR Prostate Brachytherapy*
Ananth Ravi

2:35-2:45 Question and Answer Period

2:45-3:15 **Break**

3:15-4:45 **Session 3 – Liver and Spine**

Moderator: Nicole Harnett

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to the use of SBRT in the treatment of paraspinal and liver disease.
- articulate the benefits of significant hypofractionation in these patients.
- discuss the technical challenges of delivering SBRT to these sites.

3:15-3:35 *SBRT for Spinal Metastases: How, When and Why?*
Arjun Sahgal

3:35-3:45 Question and Answer Period

3:45-4:05 *Tumour Motion Management for Liver SBRT*
Michael Velec

4:05-4:15 Question and Answer Period

4:15-4:35 *The Emerging Role of Stereotactic Body Radiotherapy
in the Management of Colorectal Liver Metastases*
William Chu

4:35-4:45 Question and Answer Period

4:45-6:00 **Poster Viewing and Reception (3rd Level, King Gallery)**

Conference Schedule / Friday May 4, 2012

7:30-8:30 **Breakfast and Registration**

8:30-8:45 **Welcome and Introduction**

Patrick Cheung, Co-Chair, Organizing Committee, UT DRO

8:45-9:30 **Keynote Address**

MR Brachytherapy for Cervical Cancer

Kari Tanderup

Objectives: In this session, the attendees will be able to

- explain the principles of image-guided brachytherapy in cervix cancer.
- discuss upcoming data from clinical trials on image guided brachytherapy.

9:30-9:45 **Question and Answer Period**

9:45-10:15 **Break**

10:15-11:45 **Session 4 – Gynecologic Cancer**

Moderators: Ida Ackerman, Michael Milosevic

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to Brachytherapy for gynecological cancers.
- describe the uncertainties and controversies inherent in delivering Brachytherapy for cervical cancer.
- discuss various approaches to quality assurance and developing standards of care when adopting new treatment techniques.

10:15-10:35 *Guidelines and Standards for Cervical Cancer Brachytherapy*

Anthony Fyles

10:35-10:45 Question and Answer Period

10:45-11:05 *Interstitial Brachytherapy for Cervical Cancer*

David D'Souza

11:05-11:15 Question and Answer Period

11:15-11:35 Panel: *Cases and Controversies in Image-Guided Brachytherapy for Cervical Cancer*

Panelists: Kari Tanderup, Anthony Fyles, David D'Souza

11:35-11:45 Question and Answer Period

11:45-1:15 **Lunch**

Conference Schedule / Friday May 4, 2012

1:15-2:45 **Session 5 – Biologic Insights**

Moderator: Lori Holden

Objectives: After this session, the attendees will be able to

- identify radiobiological mechanisms at work when significant hypofractionation is used.
- describe methods for exploiting biological and molecular characteristics to improve the therapeutic ratio in radiation therapy.

1:15-1:35 *The Biology of Hypofractionated Radiotherapy*
Bradly Wouters

1:35-1:45 Question and Answer Period

1:45-2:05 *Multiparametric MR-Imaging of Tumour Biology to Guide Prostate Cancer Radiotherapy*
Cynthia Ménard

2:05-2:15 Question and Answer Period

2:15-2:35 *Personalized Treatment of Brain Tumours: Integrating Radiotherapy and Molecular Therapeutics*
Caroline Chung

2:35-2:45 Question and Answer Period

2:45-3:15 **Break**

3:15-4:15 **Session 6 – Thoughts from the Trenches**

Moderator: Miller MacPherson

Objectives: After this session, the attendees will be able to

- appreciate the realities of new program development and the challenges that must be addressed when implementing new programs/approaches.

3:15-3:30 *Timelines and Efficiency of MR-guided Brachytherapy for Cervical Cancer*
Kitty Chan

3:30-3:35 Question and Answer Period

3:35-3:50 *Lung SBRT in Mississauga: Tips for Starting a New Program*
Hany Soliman

3:50-3:55 Question and Answer Period

3:55-4:10 *CyberKnife Radiosurgery: A Different Approach to IGRT*
Martin Shim

4:10-4:15 Question and Answer Period

Conference Schedule / Friday May 4, 2012

4:15-5:00

Debate

Be it Resolved that HDR Brachytherapy Should be the Standard of Care in Ontario for Men with Intermediate Risk Prostate Cancer.

For: Charles Catton

Opposed: Gerard Morton

Objectives: After this session, the attendees will be able to

- evaluate clinical outcomes related to the use of SBRT and HDR Brachytherapy for prostate cancers.
- emphasize the need for quality assurance and apply standards of care when adopting new treatment techniques.

5:00

Wrap Up

Patrick Cheung, Co-Chair, Organizing Committee, UT DRO